Pfizer False Claims Act Ruling Keeps High Evidentiary Standards, Limits Employee Protections
Appeals court rules that aggregate data of government expenditures are not a substitute evidence of actual false claims and that FCA does protect whistleblowers who just report regulatory violations.
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
CDER Director Woodcock announced that the drug center will soon launch the Drug Risk Management Board, which will coordinate product safety activities among the different offices; Patrizia Cavazzoni, who serves as CDER's deputy director of operations, will chair the board.